Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer

Since 2004, the clinical impact of monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) on patients with metastatic colorectal cancer (MCRC) has been clearly established. The combination of these biological agents with conventional chemotherapy has led to a significant...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Fiore, F, Sesboüé, R, Michel, P, Sabourin, J C, Frebourg, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008616/
https://www.ncbi.nlm.nih.gov/pubmed/21139621
http://dx.doi.org/10.1038/sj.bjc.6606008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008616/
https://www.ncbi.nlm.nih.gov/pubmed/21139621
http://dx.doi.org/10.1038/sj.bjc.6606008

Ejemplares similares